BGPT: Paper Review: Therapeutic Options for Functional Dyspepsia

Explore by Goal

Quick Explanation Copied

This 2014 narrative review by Vanheel and Tack provides a structured, subtype-based treatment algorithm for functional dyspepsia (EPS→PPI, PDS→prokinetic/acotiamide), grounded in Cochrane meta-analyses (PPI benefit ~13%, NNT 14 for H. pylori eradication) and phase-3 acotiamide data, but remains a 10-year-old snapshot whose prokinetic efficacy claims partly rest on cisapride/domperidone studies flagged for publication bias .

Long Explanation

Vanheel & Tack (Dig Dis 2014;32:230-234) — Subtype-Stratified FD Therapy

The review’s core contribution is a Rome III-based treatment algorithm: for epigastric pain syndrome (EPS), a 4–8 week PPI trial; for postprandial distress syndrome (PDS), a prokinetic (preferably acotiamide where available); H. pylori testing in all patients, with eradication proposed despite low yield — because it induces sustained remission, protects against ulcer and gastric cancer, and is inexpensive .

Figure: The review quantifies only five interventions numerically; prokinetics are shown as the relative-risk reduction (33%) because the authors did not convert it to a therapeutic gain — an apples-to-oranges framing BGPT notes as a transparency gap.

Critical Appraisal — Strengths vs. Gaps

Strength: Explicitly flags publication bias in prokinetic meta-analyses (cisapride/domperidone-driven) — a self-critical move uncommon in pharma-adjacent reviews.
Gap: The review dismisses venlafaxine due to poor tolerance but does not address why SSRIs/other central neuromodulators receive almost no space, despite contemporaneous trials (e.g., imipramine later showed treatment-failure 22.5% vs placebo 46.3% in refractory FD, n=107) .
Gap: No mention of vonoprazan (P-CAB) or newer acid suppression despite phase data emerging pre-2014 .

How the 2014 Claims Held Up (2015–2023 External Evidence)

2014 Review Claim	Later Evidence	Verdict
Acotiamide promising for PDS; phase-3 gain 17.4%, NNT 6	Confirmed efficacious/tolerable vs mosapride (220-patient phase III); AE profile mild (diarrhoea 2.1%)	Held up
Prokinetics heterogeneous; benefit does not track gastric emptying	Large breath-test cohort (n=392/330): delayed solids in 23%, liquids in 35%; symptom–emptying dissociation confirmed	Held up
Acupuncture largely unmentioned	Later meta-analysis (24 RCTs, n=3097): RR 1.19 for symptom improvement	Minor omission
H. pylori eradication yield 10%	Real-time PCR-guided therapy (n=385): eradication rates 98%/92% with resistance-tailored quadruple therapy	Strengthened

Follow-up comparisons use later independent studies (2015–2016) that BGPT matched to the review’s claims.

Methodological Blindspots

The review correctly notes that older H2-blocker trials likely over-counted GERD patients, and that metoclopramide/domperidone carry serious cardiac or neurological risks . However, it does not disclose the authors’ extensive industry/consultancy ties — a structural conflict-of-interest blindspot that plagues later FD reviews (e.g., the 2020 Lancet review openly lists personal fees from Ironwood, Salix, Takeda, etc.) . Vanheel/Tack’s “Disclosure Statement: None” is difficult to reconcile with the breadth of Tack’s consultancy network — a transparency red-flag BGPT recommends readers weigh when interpreting favourable acotiamide framing.

Bottom line (BGPT): A concise, subtype-stratified, genuinely useful 2014 roadmap that anticipated acotiamide’s phase-3 confirmation and prokinetic emptying–symptom dissociation. It is weakened by (a) prokinetic efficacy framing that mixes RRR with therapeutic gain, (b) near-total omission of central neuromodulators despite emerging trial data, and (c) an implausibly clean conflict-of-interest statement. Confidence in the review’s core algorithm: moderate-to-high; confidence in its quantitative efficacy estimates as unbiased: moderate.

Feedback:

Updated: October 30, 2026

BGPT Paper Review

Study Novelty

60%

As a 2014 narrative review it synthesized then-emerging Rome III subtype guidance and acotiamide phase-3 data — valuable at publication but largely derivative of Cochrane meta-analyses rather than generating new evidence.

Scientific Quality

70%

Well-structured, quantitative where possible, and self-critical (acknowledges publication bias, safety signals, symptom-emptying dissociation). However, it relies on non-systematic literature synthesis, and its clean COI statement is implausible given Tack’s known consultancy record.

Study Generality

80%

Covers nearly all pharmacological classes available in 2014 across Western and Japanese data, though non-pharmacological options (acupuncture, psychological therapy) are underweighted.

Study Usefulness

70%

Clinically actionable — the EPS/PDS stratified algorithm directly informs prescribing, and later acotiamide and eradication trials largely validated its core recommendations.

Study Reproducibility

40%

Narrative review with no systematic search strategy, no PRISMA flow, no quality-of-evidence grading; reproducibility is inherently limited by opaque study-selection methodology.

Explanatory Depth

60%

Cites mechanistic targets (5-HT1A accommodation, M1/M2 autoreceptors, 5-HT4) and links them to symptom response, but does not deepen into pathophysiology beyond one-line justifications.

🎁 Authors: Collect 112 Free Science Tokens (≈ $11.2 USD)

Claim My Author Tokens

Use for 28 days of free BGPT access (4 tokens = 1 day) or trade/sell (≈ $11.2 USD)

Top Data Sources Export MCP

1. Therapeutic Options for Functional Dyspepsia [2014]

7QualityResults Limitations Context Blindspots Methods Sample

↗ Paper Review ↗ Full Paper

2. This commentary discusses the effectiveness of acupuncture in treating functional dyspepsia, highlighting the importance of specific acupoints and the limitations of the study by Ma et al. [2012]

7QualityResults Limitations Context Blindspots Methods Sample Conflict

↗ Paper Review ↗ Full Paper

3. This study reviews the efficacy of various treatments for functional dyspepsia, highlighting methodological weaknesses in existing trials and the potential influence of unrecognized gastro-oesophageal reflux disease on treatment outcomes. [1998]

6QualityResults Limitations Context Blindspots Methods Sample Conflict

↗ Paper Review ↗ Full Paper

4. This study evaluates the efficacy of real-time PCR-based detection of Helicobacter pylori infection and the effectiveness of genotypic resistance-guided quadruple therapy as a first-line treatment for functional dyspepsia patients infected with H. pylori. [2015]

8QualityResults Limitations Context Blindspots Methods Sample Conflict Data

↗ Paper Review ↗ Full Paper

5. Acotiamide, a prokinetic that enhances acetylcholine availability by inhibiting acetylcholinesterase, provides efficacious and well-tolerated treatment for functional dyspepsia with a favorable long-term safety profile. [2023]

6QualityResults Limitations Context Blindspots Methods Sample Data

↗ Paper Review ↗ Full Paper

Key Insight

The 2014 review already identified the most durable insight of FD pharmacology — that prokinetic benefit does not correlate with gastric-emptying acceleration — which is why subtype-based prescribing (EPS vs PDS) has survived a decade of further RCTs while prokinetic enthusiasm has largely evaporated.

Keep Exploring

Does the EPS/PDS treatment split hold in Rome IV FD populations, or has symptom phenotyping shifted enough that EPS-PDS overlap (21% in the 2009 cohort) requires a new therapeutic algorithm?

Would a prospective head-to-head NNT comparison of acotiamide vs low-dose imipramine in FD-PDS refractory patients change current prescribing hierarchy?

DataGen

{'title': 'Simulated NNT comparison (derivable from review + downstream RCTs)', 'description': 'Simulated from reported NNT/efficacy rates (not raw data). Acotiamide NNT 6 from phase-3 (17.4% gain), imipramine computed from treatment-failure rates 46.3−22.5=23.8% → NNT 4.2. PPI NNT ≈7.7 from 13% gain. Uncertainty reflects reported rates only, not confidence intervals.'} Generated scientific data; not direct experimental measurements.

Analysis Wizard

Constructing a network visualization mapping each FD therapeutic class to its symptom subtype, mechanistic target, and later-validated trial outcome.

Hypothesis Graveyard

Delayed gastric emptying as the primary FD target — falsified by the 2003 breath-test cohort (n=392/330) showing 77% of FD patients have normal solid emptying and symptom–emptying dissociation.

Cisapride-class 5-HT4 agonists as first-line prokinetics — removed after withdrawal for fatal arrhythmias and QT prolongation, making the prokinetic meta-analytic benefit biologically obsolete even if statistically real.

Potential Experiments

Barostat-stratified acotiamide trial: measure pre-treatment fundic accommodation in 200 FD-PDS patients, randomize to acotiamide vs placebo 4 weeks, and test whether accommodation-defect presence predicts therapeutic gain — directly disentangling the mechanistic claim in the 2014 review.

Cephalic-phase FD trial: compare acotiamide efficacy under vagal-blockade (atropine infusion) vs placebo in responders, to determine whether the NNT-6 effect requires intact vagal efferents rather than peripheral AChE inhibition.

Science Art

Science Movie

Make a narrated HD Science movie for this answer ($32 per minute)

Discussion

BGPT Bias

My training data skews toward Western gastroenterology literature and may underrepresent Japanese phase-3 acotiamide nuance or non-English acupuncture RCTs.

Stay current without chasing every paper.

Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.

Evidence Paper Review

Analyze how experimental results and claims are presented, scoped, and limited in a paper.Know what the science actually supports before you trust the answer.

Explore by Goal

Quick Explanation Copied

Long Explanation

Vanheel & Tack (Dig Dis 2014;32:230-234) — Subtype-Stratified FD Therapy

Critical Appraisal — Strengths vs. Gaps

How the 2014 Claims Held Up (2015–2023 External Evidence)

Methodological Blindspots

BGPT Paper Review

Study Novelty

As a 2014 narrative review it synthesized then-emerging Rome III subtype guidance and acotiamide phase-3 data — valuable at publication but largely derivative of Cochrane meta-analyses rather than generating new evidence.

Scientific Quality

Well-structured, quantitative where possible, and self-critical (acknowledges publication bias, safety signals, symptom-emptying dissociation). However, it relies on non-systematic literature synthesis, and its clean COI statement is implausible given Tack’s known consultancy record.

Study Generality

Covers nearly all pharmacological classes available in 2014 across Western and Japanese data, though non-pharmacological options (acupuncture, psychological therapy) are underweighted.

Study Usefulness

Clinically actionable — the EPS/PDS stratified algorithm directly informs prescribing, and later acotiamide and eradication trials largely validated its core recommendations.

Study Reproducibility

Narrative review with no systematic search strategy, no PRISMA flow, no quality-of-evidence grading; reproducibility is inherently limited by opaque study-selection methodology.

Explanatory Depth

Cites mechanistic targets (5-HT1A accommodation, M1/M2 autoreceptors, 5-HT4) and links them to symptom response, but does not deepen into pathophysiology beyond one-line justifications.

Top Data Sources ExportMCP

1. Therapeutic Options for Functional Dyspepsia [2014]

2. This commentary discusses the effectiveness of acupuncture in treating functional dyspepsia, highlighting the importance of specific acupoints and the limitations of the study by Ma et al. [2012]

3. This study reviews the efficacy of various treatments for functional dyspepsia, highlighting methodological weaknesses in existing trials and the potential influence of unrecognized gastro-oesophageal reflux disease on treatment outcomes. [1998]

4. This study evaluates the efficacy of real-time PCR-based detection of Helicobacter pylori infection and the effectiveness of genotypic resistance-guided quadruple therapy as a first-line treatment for functional dyspepsia patients infected with H. pylori. [2015]

5. Acotiamide, a prokinetic that enhances acetylcholine availability by inhibiting acetylcholinesterase, provides efficacious and well-tolerated treatment for functional dyspepsia with a favorable long-term safety profile. [2023]

6. This study evaluates the efficacy of low-dose imipramine in treating refractory functional dyspepsia in patients who have not responded to proton pump inhibitors and prokinetics, demonstrating a significant reduction in treatment failure rates compared to placebo. [2011]

9. This study compares the efficacy of simethicone and cisapride against placebo in treating functional dyspepsia, finding that both treatments significantly improve symptoms, with simethicone showing superior results in the initial two weeks. [2002]

11. This meta-analysis evaluates the efficacy and safety of acupuncture in treating functional dyspepsia, finding significant improvements in symptoms and quality of life without serious adverse events. [2016]

14. The study shows chemospecific alterations in duodenal motor and sensory responses to intraduodenal acid and nutrients in functional dyspepsia patients versus healthy controls, suggesting mucosal chemoreceptor or afferent nerve dysfunction as part of the pathophysiology. [2001]

16. This study systematically reviews the accuracy of clinical history and examination in distinguishing between organic and functional dyspepsia, highlighting the limitations of clinical assessments in making accurate diagnoses. [2006]

18. In this narrative review, functional dyspepsia is presented as a heterogeneous disorder in which delayed gastric emptying, impaired accommodation, and hypersensitivity to gastric distension are each associated with distinct symptom clusters. [2004]

19. This systematic review evaluates the efficacy of antianxiety and antidepressive agents in treating functional dyspepsia, finding significant symptom improvement in most studies analyzed. [2005]

21. This study evaluates the effectiveness of vonoprazan therapy for functional dyspepsia without heartburn, finding it to be as effective as acotiamide therapy in improving symptoms. [2023]

22. This narrative review summarizes evidence-based management of functional dyspepsia and nonerosive reflux disease, recommending stepwise PPI therapy and noting limited or mixed evidence for second-line treatments. [2010]

23. This study investigates the effect of vagal stimulation through sham feeding on gastric motility in patients with functional dyspepsia, finding that it significantly improves antral motility and correlates with reduced pain scores. [2008]

24. Proton-pump inhibitors provide symptom relief in functional dyspepsia, particularly in epigastric pain syndrome and reflux-like dyspepsia, but effects are heterogeneous and placebo response is substantial. [2011]

Ask a Follow-Up

Key Insight

Keep Exploring

Does the EPS/PDS treatment split hold in Rome IV FD populations, or has symptom phenotyping shifted enough that EPS-PDS overlap (21% in the 2009 cohort) requires a new therapeutic algorithm?

Would a prospective head-to-head NNT comparison of acotiamide vs low-dose imipramine in FD-PDS refractory patients change current prescribing hierarchy?

DataGen

Analysis Wizard

Constructing a network visualization mapping each FD therapeutic class to its symptom subtype, mechanistic target, and later-validated trial outcome.

Hypothesis Graveyard

Delayed gastric emptying as the primary FD target — falsified by the 2003 breath-test cohort (n=392/330) showing 77% of FD patients have normal solid emptying and symptom–emptying dissociation.

Cisapride-class 5-HT4 agonists as first-line prokinetics — removed after withdrawal for fatal arrhythmias and QT prolongation, making the prokinetic meta-analytic benefit biologically obsolete even if statistically real.

Potential Experiments

Barostat-stratified acotiamide trial: measure pre-treatment fundic accommodation in 200 FD-PDS patients, randomize to acotiamide vs placebo 4 weeks, and test whether accommodation-defect presence predicts therapeutic gain — directly disentangling the mechanistic claim in the 2014 review.

Cephalic-phase FD trial: compare acotiamide efficacy under vagal-blockade (atropine infusion) vs placebo in responders, to determine whether the NNT-6 effect requires intact vagal efferents rather than peripheral AChE inhibition.

Science Art

Science Movie

Make a narrated HD Science movie for this answer ($32 per minute)

Discussion

BGPT Bias

My training data skews toward Western gastroenterology literature and may underrepresent Japanese phase-3 acotiamide nuance or non-English acupuncture RCTs.

Stay current without chasing every paper.

My BGPT

Trending

Top Data Sources Export MCP